Literature DB >> 29141165

Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer.

Naiyer A Rizvi1, Solange Peters1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29141165     DOI： 10.1056/NEJMe1711430

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  18 in total

1.  Durvalumab for non-resectable stage IIIB non-small cell lung cancer-a small step or a big leap?

Authors:  Wolfram C M Dempke; Klaus Fenchel
Journal:  Transl Lung Cancer Res       Date:  2018-04

Review 2.  Advanced non-small cell lung cancer: the role of PD-L1 inhibitors.

Authors:  David F Heigener; Martin Reck
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.

Authors:  Steven D Criss; Meghan J Mooradian; Deirdre F Sheehan; Leyre Zubiri; Melissa A Lumish; Justin F Gainor; Kerry L Reynolds; Chung Yin Kong
Journal:  JAMA Oncol       Date:  2019-03-01       Impact factor: 31.777

4.  Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.

Authors:  Zhao Zhang; Jun Jiang; Xiaodong Wu; Mengyao Zhang; Dan Luo; Renyu Zhang; Shiyou Li; Youwen He; Huijie Bian; Zhinan Chen
Journal:  Front Med       Date:  2019-02-05       Impact factor: 4.592

5.  A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-Small Cell Lung Cancer Patients.

Authors:  Carlos Camps; Eloísa Jantus-Lewintre; Alejandro Herreros-Pomares; Paula Doria; Sandra Gallach; Marina Meri-Abad; Ricardo Guijarro; Silvia Calabuig-Fariñas
Journal:  Ann Surg Oncol       Date:  2022-09-21       Impact factor: 4.339

6.  Treatment Patterns for Patients With Unresected Stage III NSCLC: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database.

Authors:  Shijie Shang; Ruiyang Wang; Fei Wang; Meng Wu; Dawei Chen; Jinming Yu
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

7.  LINC00467 is up-regulated by TDG-mediated acetylation in non-small cell lung cancer and promotes tumor progression.

Authors:  Yuxing Zhu; Jingjing Li; Hao Bo; Dong He; Mengqing Xiao; Liang Xiang; Lian Gong; Yi Hu; Yeyu Zhang; Yaxin Cheng; Liping Deng; Rongrong Zhu; Yanni Ma; Ke Cao
Journal:  Oncogene       Date:  2020-08-14       Impact factor: 9.867

8.  G9a regulates tumorigenicity and stemness through genome-wide DNA methylation reprogramming in non-small cell lung cancer.

Authors:  Rajendra P Pangeni; Lu Yang; Keqiang Zhang; Jinhui Wang; Wendong Li; Chao Guo; Xinwei Yun; Ting Sun; Jami Wang; Dan J Raz
Journal:  Clin Epigenetics       Date:  2020-06-17       Impact factor: 6.551

9.  Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for non-small cell lung cancer.

Authors:  Michela Terlizzi; Chiara Colarusso; Ilaria De Rosa; Nicolina De Rosa; Pasquale Somma; Carlo Curcio; Alessandro Sanduzzi; Pietro Micheli; Antonio Molino; Antonello Saccomanno; Rosario Salvi; Rita P Aquino; Aldo Pinto; Rosalinda Sorrentino
Journal:  Oncotarget       Date:  2018-04-10

Review 10.  Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer.

Authors:  Michael R Shafique; Lary A Robinson; Scott Antonia
Journal:  Cancer Manag Res       Date:  2018-05-01       Impact factor: 3.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.